Neuroleptic drug-induced changes in platelet levels

Area of Science:

• Psychiatry
• Pharmacology
• Hematology

Background:

• Antipsychotic medications are widely used in psychiatric care.
• Thrombocytopenia is a potential adverse effect of some medications.
• The incidence of thrombocytopenia with different antipsychotics requires further investigation.

Purpose of the Study:

• To prospectively investigate the incidence of thrombocytopenia in psychiatric inpatients receiving haloperidol, chlorpromazine, fluphenazine decanoate, or no drug therapy.
• To compare platelet levels and the occurrence of thrombocytopenia across different antipsychotic treatment groups.

Main Methods:

• Prospective study design.
• Inclusion of matched psychiatric inpatients receiving haloperidol, chlorpromazine, fluphenazine decanoate, or no drug therapy (control).
• Statistical analysis of thrombocytopenia incidence, mean platelet levels, and pre-treatment platelet values.

Main Results:

• No statistically significant differences in thrombocytopenia incidence or mean platelet levels were observed between the groups.
• Phenothiazine-treated groups showed significantly more patients with low-normal platelet levels compared to haloperidol and control groups.
• Retrospective analysis revealed significant decreases in platelet values in phenothiazine-treated patients but not in the haloperidol group.

Conclusions:

• Neuroleptic drug-induced thrombocytopenia is rare.
• Phenothiazine antipsychotics may be more frequently associated with decreased platelet values and low-normal platelet levels than haloperidol.